MoonLake Immunotherapeutics
MLTX
$16.47
-$0.03-0.18%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 21.78% | 34.50% | 38.44% | 49.78% | 48.05% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 33.58% | 56.58% | 71.11% | 111.17% | 156.21% |
| Operating Income | -33.58% | -56.58% | -71.11% | -111.17% | -156.21% |
| Income Before Tax | -47.79% | -75.22% | -89.91% | -158.70% | -208.07% |
| Income Tax Expenses | 182.15% | 195.89% | 116.67% | 41.61% | 71.47% |
| Earnings from Continuing Operations | -48.07% | -75.52% | -89.97% | -158.29% | -207.55% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -47.43% | -8.93% | 30.07% | 62.63% | -13.89% |
| Net Income | -49.68% | -77.05% | -91.13% | -160.62% | -221.44% |
| EBIT | -33.58% | -56.58% | -71.11% | -111.17% | -156.21% |
| EBITDA | -33.19% | -56.09% | -70.93% | -111.81% | -157.26% |
| EPS Basic | -37.38% | -67.98% | -86.40% | -157.74% | -208.47% |
| Normalized Basic EPS | -38.01% | -68.61% | -87.06% | -159.66% | -218.89% |
| EPS Diluted | -37.38% | -67.98% | -86.40% | -157.74% | -208.47% |
| Normalized Diluted EPS | -38.01% | -68.61% | -87.06% | -159.66% | -218.89% |
| Average Basic Shares Outstanding | 9.52% | 5.48% | 2.54% | 1.87% | 5.67% |
| Average Diluted Shares Outstanding | 9.52% | 5.48% | 2.54% | 1.87% | 5.67% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |